Basic information Safety Supplier Related

ML277

Basic information Safety Supplier Related

ML277 Basic information

Product Name:
ML277
Synonyms:
  • VU0458298-2, VU0458298-3
  • ML277
  • (2R)-N-[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]-1-(4-methylphenyl)sulfonylpiperidine-2-carboxamide
  • (R)-N-(4-(4-Methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide
  • CID-53347902
  • ML277;ML 277; ML-277
  • (2R)-N-[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]-1-[(4-methylphenyl) sulfonyl]-2-piperidinecarboxamide
  • (2R)-N-[4-(4-Methoxyphenyl)-2-thiazolyl]-1-[(4-methylphenyl)sulfonyl]-2-piperidinecarboxamide
CAS:
1401242-74-7
MF:
C23H25N3O4S2
MW:
471.59
Product Categories:
  • API
Mol File:
1401242-74-7.mol
More
Less

ML277 Chemical Properties

Density 
1.341±0.06 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: 5 mg/ml
form 
powder
pka
8.37±0.70(Predicted)
color 
white to beige
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
22-36
Safety Statements 
26
WGK Germany 
3
More
Less

ML277 Usage And Synthesis

Description

Potassium (K+) channels are categorized by their mode of activation and the number of transmembrane segments. The voltage-gated six-transmembrane K+ channels include KCNQ1, first recognized for its role in cardiac function and subsequently in hearing, gastrointestinal chloride secretion, and other processes. ML-277 is a potent activator of KCNQ1 channels (EC50 = 260 nM). The EC50 value of this compound at the related channels KCNQ2, KCNQ4, and hERG exceeds 30 μM. ML-277 potentiates both homomultimeric KCNQ1 channels and unsaturated heteromultimeric (KCNQ1/KCNE1) channels in model cardiomyocytes and augments delayed rectifier K+ current in cultured human cardiomyocytes.

Uses

ML277 has been used as the KCNQ1 activator to treat?cells in lung metastasis?assay.

Biochem/physiol Actions

ML277 is a potent activator of KCNQ1 (Kv7.1) channels with >100-fold selectivity versus KCNQ2 and KCNQ4 and no activity against the hERG potassium channel up to 30 μM. KCNQ1 is a voltage-gated potassium channel required for repolarization phase of the cardiac action potential. Mutations in the KCNQ1 gene are associated with long QT syndrome (LQTS), a disorder in which the heart muscles take longer than normal to recover after each heart beat and can lead to dangerous arrhythmias such as atrial fibrillation. Activators of KCNQ1 channels could have potential use in treatments of LQTS. ML277 is the first selective and potent activator found, with an EC50 of 260 nM.

storage

Store at -20°C

ML277Supplier

Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
EnliPharma Technology Co., Ltd
Tel
0551-66399836 18955197623
Email
sales@enlipharma.com
TargetMol Chemicals Inc.
Tel
021-33632979 15002134094
Email
marketing@targetmol.com
LETOPHARM LIMITED
Tel
+86-21-5821 5861
Email
sales@letopharm.com
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com